Amid national angst over prescription drug pricing, Express Scripts (ESRX), the big pharmacy benefit manager, is touting a new scheme it says will lessen the behind-the-scenes role that rebates play in rising costs.
The idea targets the complicated calculus used by drug makers and pharmacy benefit managers for negotiating formularies, the all-important lists of medicines for preferred insurance coverage. By doing so, Express Scripts argued costs should decline for some consumers, while appeasing critics — including Trump administration officials — who have urged these companies to eliminate their reliance on rebates.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
